MARKET

AYTU

AYTU

Aytu BioScience
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.30
+0.64
+8.36%
After Hours: 8.23 -0.07 -0.84% 19:50 01/20 EST
OPEN
7.70
PREV CLOSE
7.66
HIGH
8.37
LOW
7.55
VOLUME
904.92K
TURNOVER
--
52 WEEK HIGH
29.90
52 WEEK LOW
3.350
MARKET CAP
143.14M
P/E (TTM)
-3.6620
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
A Specialty Consolidator: Biopharma Aytu Looks To Acquisitions And Licensing To Propel Growth Through 2021
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational p...
Benzinga · 01/06 12:58
Aytu BioScience completes safety study in critically ill COVID-19 patients
Aytu BioScience (AYTU) is up 4.3% in premarket trading as the company announces the completion of the safety study for the use of ultraviolet A light as a COVID-19 treatment.The single-center, U.S.-based study evaluated
Seekingalpha · 12/28/2020 13:32
Aytu BioSicence Reports Completion Of Healight Safety Study In COVID-19 Patients
Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced the completion of the safety
Benzinga · 12/28/2020 13:06
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients
ACCESSWIRE · 12/28/2020 13:05
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 PatientsENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScience, Inc.
ACCESSWIRE · 12/28/2020 13:05
Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ("Aytu" or "the Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closin...
ACCESSWIRE · 12/15/2020 17:00
Aytu BioScience Announces Closing of $28.75 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
ACCESSWIRE · 12/15/2020 17:00
Aytu BioScience to Present at the LD Micro Virtual Investor Conference on Tuesday, December 15 at 2:20pm ET
ENGLEWOOD, CO / ACCESSWIRE / December 14, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that management will ...
ACCESSWIRE · 12/14/2020 13:01
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AYTU. Analyze the recent business situations of Aytu BioScience through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AYTU stock price target is 23.60 with a high estimate of 30.00 and a low estimate of 17.20.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 3.89M
% Owned: 22.58%
Shares Outstanding: 17.25M
TypeInstitutionsShares
Increased
20
421.33K
New
31
-37.78K
Decreased
18
78.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Chairman/Chief Executive Officer/Director
Joshua Disbrow
Chief Financial Officer/Treasurer/Secretary
David Green
Chief Operating Officer
Jarrett Disbrow
Executive Vice President
Matthew Phillips
Director
Steven Boyd
Director
Ketan Mehta
Independent Director
Gary Cantrell
Independent Director
Carl Dockery
Independent Director
John Donofrio
Independent Director
Michael Macaluso
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AYTU
Aytu BioScience, Inc. is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The primary care portfolio includes Natesto, the nasal formulation of testosterone for men with hypogonadism, ZolpiMist, the oral spray prescription sleep aid, and Tuzistra XR, the 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; Cefaclor, a second-generation cephalosporin antibiotic suspension; Karbinal ER, an extended-release carbinoxamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency.
More

Webull offers kinds of Aytu Bioscience Inc stock information, including NASDAQ:AYTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYTU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AYTU stock methods without spending real money on the virtual paper trading platform.